Hypertension Journal

Register      Login

VOLUME 3 , ISSUE 3 ( July-September, 2017 ) > List of Articles


Cardiovascular Protective Actions of Sodium Glucose Cotransporter 2 Inhibitors

Shamanna S Iyengar

Citation Information : Iyengar SS. Cardiovascular Protective Actions of Sodium Glucose Cotransporter 2 Inhibitors. Hypertens J 2017; 3 (3):161-165.

DOI: 10.5005/jp-journals-10043-0088

License: CC BY 3.0

Published Online: 00-09-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


“Current management of diabetes is characterized by opportunities, options, and obstacles.”

—Dr Sanjay Kalra


How to cite this article

Iyengar SS. Cardiovascular Protective Actions of Sodium Glucose Cotransporter 2 Inhibitors. Hypertens J 2017;3(3):161-165.

PDF Share
  1. Nations within a nation: variations in epidemiological transition across the states of India, 1990—2016 in the Global Burden of Disease Study. Lancet 2017 Dec;390(10111):2437-2460.
  2. India — diabetes capital of the world: now heading towards hypertension. J Assoc Physicians India 2007 May;55:323-324.
  3. India towards diabetes control: key issues. Australas Med J 2013 Oct;6(10):524-531.
  4. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta (GA): CDC; 2011.
  5. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 Jul;339(4):229-234.
  6. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009 Feb;26(2):142-148.
  7. Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. J Gen Intern Med 2016 Apr;31(4):387-393.
  8. Trends in hypertension prevalence, awareness, treatment and control in older Mexican Americans, 1993-2005. Ann Epidemiol 2011 Jan;21(1):15-25.
  9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 Sep;352(9131):837-853.
  10. Novel diabetes drugs and the cardiovascular specialist. J Am Coll Cardiol 2017 May;69(21):2646-2656.
  11. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Euro Heart J 2015 Sep;36(34):2288-2296.
  12. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose cotransporter 2 inhibitor. Clin Pharmacokinet 2014 Mar;53(3):213-225.
  13. Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension. Diabetologia 2013 Nov;56(Suppl 1):S377.
  14. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 2015 Mar;38(3):355-364.
  15. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One 2014 Aug;9(8):e105638.
  16. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014 Feb;16(2):159-169.
  17. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 Nov;373(22):2117-2128.
  18. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease a subanalysis of EMPA-REG OUTCOME. Circulation 2017 Nov;136:032031.
  19. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017 Aug;377(7):644-657.
  20. Canagliflozin for primary and secondary prevention of cardiovascular events results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2017 Nov;137:032038.
  21. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol 2016 Feb;15:37.
  22. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016 May;4(5):411-419.
  23. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016 Sep;134(10):752-772.
  24. Pharmacologic approaches to glycemic treatment. Diabetes Care 2017 Jan;40(Suppl 1):S64-S74.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.